Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 5Recruiting 3Withdrawn 1Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 6Neoplasm Metastasis 5Colorectal Neoplasms 4Solid Tumor 3Stomach Neoplasms 2Melanoma 2Endometrial Neoplasms 2Turcot syndrome 1Triple Negative Breast Neoplasms 1Thyroid Carcinoma, Anaplastic 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sarcoma 1Rectal Neoplasms 1Neuroendocrine Tumors 1Neoplasms 1Metastatic Solid Tumors 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Extranodal NK-T-Cell 1Lymphoma 1Extensive Stage Small Cell Lung Cancer 1Esophageal Squamous Cell Carcinoma 1Colorectal Neoplasms, Hereditary Nonpolyposis 1Colonic Neoplasms 1Breast Neoplasms 1Advanced Solid Tumors 1Adenocarcinoma 1

Interventions

pembrolizumab 20Carboplatin 14Cyclophosphamide 12atezolizumab 11Paclitaxel 10Albumin-Bound Paclitaxel 8Capecitabine 7Nivolumab 6130-nm albumin-bound paclitaxel 6spartalizumab 5fludarabine 5Taxes 5Gemcitabine 5talazoparib 4bintrafusp alfa protein, human 4avelumab 4Cisplatin 4sacituzumab govitecan 3olaparib 3entinostat 3Leucovorin 3Ipilimumab 3Immunoglobulin G 3Drug Therapy 3Doxorubicin 3Docetaxel 3Biopsy 32,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 3trilaciclib 2eribulin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Triple Negative Breast Neoplasms × tislelizumab × Clear all
NCT04577963 2025-07-14

A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors

Hutchmed

Phase 1/2 Terminated
52 enrolled 23 charts
BreastGastrointestinalGynecologic

Breast Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡